Risk-tailored treatment of splenic marginal zone lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Splenic marginal zone lymphoma (SMZL) is a rare B-cell lymphoproliferative disorder.
• Typically affects elderly patients and involves the spleen, peripheral blood, and bone marrow, sparing lymph nodes.
• Pathogenesis involves chronic antigen stimulation leading to B-cell proliferation, with NOTCH2 and NFk-B signaling playing key roles.

Purpose of the Study:

• To review the pathogenesis, prognosis, and tailored treatment strategies for SMZL.
• To highlight the significance of NOTCH2 mutations and progression risk factors.
• To guide management decisions based on patient risk and health status.

Main Methods:

• Literature review of SMZL pathogenesis, clinical course, and treatment options.
• Analysis of progression risk factors including nodal/extra-nodal involvement, lymphocytosis, anemia, and thrombocytopenia.
• Discussion of prognostic scoring systems and their impact on survival.

Main Results:

• NOTCH2 mutations are found in 20% of SMZL cases, contributing to neoplastic proliferation.
• Progression to diffuse large B-cell lymphoma occurs in 10-15% of patients.
• A prognostic score identifies high-risk patients (≥2 points) with <5 years median survival.

Conclusions:

• Tailored treatment is crucial for SMZL management.
• Low-risk, asymptomatic patients may benefit from a 'watch and wait' approach.
• Symptomatic patients require treatment, ranging from splenectomy to rituximab-based therapies.